| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sarcoma, Synovial | 10 | 2022 | 119 | 2.160 |
Why?
|
| Solitary Fibrous Tumors | 3 | 2011 | 44 | 1.090 |
Why?
|
| Hemangiopericytoma | 3 | 2011 | 56 | 0.830 |
Why?
|
| Soft Tissue Neoplasms | 4 | 2023 | 882 | 0.800 |
Why?
|
| Gastrointestinal Stromal Tumors | 6 | 2018 | 297 | 0.560 |
Why?
|
| Antigens, Neoplasm | 4 | 2023 | 1506 | 0.390 |
Why?
|
| Hemangiosarcoma | 2 | 2010 | 234 | 0.380 |
Why?
|
| Hemangioendothelioma, Epithelioid | 1 | 2010 | 39 | 0.360 |
Why?
|
| Dacarbazine | 1 | 2011 | 485 | 0.330 |
Why?
|
| Oncogene Proteins, Fusion | 4 | 2020 | 755 | 0.320 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2010 | 355 | 0.320 |
Why?
|
| Bone Neoplasms | 5 | 2022 | 2576 | 0.310 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2011 | 1533 | 0.300 |
Why?
|
| Osteosarcoma | 3 | 2022 | 929 | 0.290 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 9 | 2022 | 15862 | 0.280 |
Why?
|
| Antibodies, Monoclonal, Humanized | 4 | 2022 | 3251 | 0.230 |
Why?
|
| Leiomyosarcoma | 2 | 2016 | 223 | 0.230 |
Why?
|
| Sarcoma | 4 | 2023 | 1725 | 0.220 |
Why?
|
| Chondrosarcoma | 2 | 2019 | 216 | 0.220 |
Why?
|
| Sarcoma, Ewing | 2 | 2017 | 406 | 0.210 |
Why?
|
| Signal Transduction | 4 | 2020 | 11965 | 0.200 |
Why?
|
| Sarcoma, Alveolar Soft Part | 1 | 2022 | 75 | 0.200 |
Why?
|
| Membrane Proteins | 3 | 2022 | 2819 | 0.190 |
Why?
|
| Foot | 1 | 2021 | 104 | 0.190 |
Why?
|
| Liposarcoma | 1 | 2022 | 214 | 0.190 |
Why?
|
| Adult | 28 | 2022 | 77950 | 0.190 |
Why?
|
| Hand | 1 | 2021 | 170 | 0.180 |
Why?
|
| Liposarcoma, Myxoid | 1 | 2020 | 38 | 0.180 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2021 | 6207 | 0.180 |
Why?
|
| Neovascularization, Pathologic | 3 | 2016 | 1547 | 0.180 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2019 | 1248 | 0.180 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2018 | 600 | 0.180 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2019 | 35 | 0.180 |
Why?
|
| Receptors, Antigen, T-Cell | 3 | 2022 | 1146 | 0.170 |
Why?
|
| Pyrimidines | 4 | 2019 | 3518 | 0.170 |
Why?
|
| Colitis | 1 | 2022 | 340 | 0.170 |
Why?
|
| Aged | 24 | 2022 | 70117 | 0.170 |
Why?
|
| Middle Aged | 26 | 2022 | 86204 | 0.170 |
Why?
|
| Young Adult | 14 | 2021 | 21445 | 0.160 |
Why?
|
| Sulfonamides | 2 | 2019 | 1823 | 0.160 |
Why?
|
| SMARCB1 Protein | 1 | 2018 | 109 | 0.160 |
Why?
|
| Treatment Outcome | 15 | 2023 | 32848 | 0.150 |
Why?
|
| Imatinib Mesylate | 3 | 2018 | 1665 | 0.150 |
Why?
|
| Chondrosarcoma, Mesenchymal | 1 | 2017 | 17 | 0.150 |
Why?
|
| Adoptive Transfer | 1 | 2019 | 446 | 0.150 |
Why?
|
| Molecular Targeted Therapy | 3 | 2017 | 2330 | 0.150 |
Why?
|
| Humans | 41 | 2023 | 261506 | 0.150 |
Why?
|
| T-Lymphocytes | 2 | 2019 | 3869 | 0.140 |
Why?
|
| Ifosfamide | 1 | 2017 | 344 | 0.140 |
Why?
|
| Phenylurea Compounds | 2 | 2017 | 580 | 0.140 |
Why?
|
| Antineoplastic Agents | 6 | 2021 | 14289 | 0.140 |
Why?
|
| Pneumonia | 1 | 2022 | 751 | 0.140 |
Why?
|
| Paraganglioma | 1 | 2017 | 170 | 0.130 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2017 | 221 | 0.130 |
Why?
|
| Cancer Care Facilities | 1 | 2020 | 884 | 0.130 |
Why?
|
| Surgical Procedures, Operative | 1 | 2019 | 383 | 0.130 |
Why?
|
| Troponin I | 1 | 2016 | 127 | 0.130 |
Why?
|
| Male | 25 | 2023 | 123000 | 0.130 |
Why?
|
| Pheochromocytoma | 1 | 2017 | 281 | 0.130 |
Why?
|
| Doxorubicin | 3 | 2017 | 3005 | 0.120 |
Why?
|
| Adolescent | 12 | 2021 | 31252 | 0.120 |
Why?
|
| Radiosurgery | 1 | 2023 | 1330 | 0.120 |
Why?
|
| Anthracyclines | 1 | 2016 | 331 | 0.120 |
Why?
|
| Female | 25 | 2021 | 141928 | 0.120 |
Why?
|
| Neoplasm Metastasis | 5 | 2019 | 5112 | 0.120 |
Why?
|
| Point-of-Care Systems | 1 | 2016 | 196 | 0.120 |
Why?
|
| Biological Products | 1 | 2017 | 274 | 0.120 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2023 | 1763 | 0.120 |
Why?
|
| Aged, 80 and over | 13 | 2022 | 29902 | 0.120 |
Why?
|
| Retrospective Studies | 10 | 2023 | 37905 | 0.110 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2016 | 343 | 0.110 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2016 | 10035 | 0.110 |
Why?
|
| Epigenesis, Genetic | 1 | 2020 | 1399 | 0.110 |
Why?
|
| Vincristine | 1 | 2017 | 1511 | 0.110 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2017 | 489 | 0.110 |
Why?
|
| Chromatin | 1 | 2018 | 942 | 0.110 |
Why?
|
| Solitary Fibrous Tumor, Pleural | 1 | 2012 | 5 | 0.110 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2014 | 347 | 0.110 |
Why?
|
| Hydroxamic Acids | 1 | 2015 | 442 | 0.110 |
Why?
|
| Disease-Free Survival | 7 | 2021 | 10001 | 0.100 |
Why?
|
| Radiotherapy | 1 | 2019 | 1824 | 0.100 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2016 | 986 | 0.100 |
Why?
|
| HLA-A Antigens | 2 | 2023 | 102 | 0.100 |
Why?
|
| Bevacizumab | 2 | 2014 | 938 | 0.100 |
Why?
|
| Fibroblast Growth Factor 7 | 1 | 2010 | 30 | 0.100 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2015 | 612 | 0.100 |
Why?
|
| Pyridines | 1 | 2017 | 1244 | 0.090 |
Why?
|
| Abdominal Neoplasms | 1 | 2012 | 231 | 0.090 |
Why?
|
| Facial Neoplasms | 1 | 2010 | 84 | 0.090 |
Why?
|
| Rhabdomyosarcoma | 1 | 2013 | 341 | 0.090 |
Why?
|
| Heart Diseases | 1 | 2016 | 732 | 0.090 |
Why?
|
| Stomatitis | 1 | 2010 | 183 | 0.090 |
Why?
|
| Orbital Neoplasms | 1 | 2011 | 224 | 0.090 |
Why?
|
| Combined Modality Therapy | 6 | 2019 | 8865 | 0.090 |
Why?
|
| Scalp | 1 | 2010 | 156 | 0.080 |
Why?
|
| Repressor Proteins | 1 | 2016 | 1664 | 0.080 |
Why?
|
| Uterine Neoplasms | 1 | 2013 | 545 | 0.080 |
Why?
|
| Calmodulin-Binding Proteins | 1 | 2008 | 86 | 0.080 |
Why?
|
| Phosphorylcholine | 1 | 2008 | 54 | 0.080 |
Why?
|
| Corneal Ulcer | 1 | 2008 | 49 | 0.080 |
Why?
|
| Pleural Neoplasms | 1 | 2012 | 470 | 0.080 |
Why?
|
| Head and Neck Neoplasms | 1 | 2023 | 3976 | 0.080 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2016 | 2488 | 0.080 |
Why?
|
| Child, Preschool | 2 | 2021 | 16273 | 0.070 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2014 | 1546 | 0.070 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2014 | 1283 | 0.070 |
Why?
|
| Tumor Microenvironment | 3 | 2022 | 2864 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 2 | 2022 | 4367 | 0.070 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2010 | 551 | 0.070 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2014 | 1756 | 0.070 |
Why?
|
| Intestinal Neoplasms | 1 | 2008 | 189 | 0.070 |
Why?
|
| Indazoles | 2 | 2019 | 297 | 0.070 |
Why?
|
| Neoplasm Staging | 6 | 2018 | 13658 | 0.070 |
Why?
|
| Child | 4 | 2021 | 29154 | 0.070 |
Why?
|
| Biomarkers | 3 | 2022 | 5047 | 0.060 |
Why?
|
| Piperazines | 2 | 2010 | 2101 | 0.060 |
Why?
|
| Models, Biological | 1 | 2012 | 3254 | 0.060 |
Why?
|
| Prognosis | 6 | 2019 | 21713 | 0.050 |
Why?
|
| Follow-Up Studies | 5 | 2019 | 14889 | 0.050 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2015 | 3552 | 0.050 |
Why?
|
| RNA-Binding Proteins | 1 | 2008 | 984 | 0.050 |
Why?
|
| Lung Neoplasms | 1 | 2023 | 11538 | 0.050 |
Why?
|
| Survival Rate | 4 | 2019 | 12221 | 0.050 |
Why?
|
| Translocation, Genetic | 2 | 2020 | 1245 | 0.050 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2023 | 406 | 0.040 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2019 | 107 | 0.040 |
Why?
|
| Neoplasms | 2 | 2016 | 15193 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2014 | 4757 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2018 | 3890 | 0.040 |
Why?
|
| Genetic Engineering | 1 | 2019 | 288 | 0.040 |
Why?
|
| Administration, Oral | 2 | 2015 | 1544 | 0.040 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2019 | 675 | 0.040 |
Why?
|
| Proportional Hazards Models | 2 | 2016 | 4988 | 0.040 |
Why?
|
| Macrophage Colony-Stimulating Factor | 1 | 2016 | 72 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2019 | 665 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2020 | 1546 | 0.040 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2019 | 604 | 0.040 |
Why?
|
| Breast Neoplasms | 1 | 2021 | 15694 | 0.040 |
Why?
|
| Tibia | 1 | 2017 | 131 | 0.040 |
Why?
|
| Immunohistochemistry | 2 | 2019 | 7548 | 0.030 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2018 | 467 | 0.030 |
Why?
|
| Patient Selection | 1 | 2023 | 2055 | 0.030 |
Why?
|
| Heart Failure | 1 | 2010 | 2516 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2017 | 9180 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2018 | 1077 | 0.030 |
Why?
|
| Cardiotoxicity | 1 | 2016 | 155 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2022 | 1586 | 0.030 |
Why?
|
| Mutation | 1 | 2015 | 15179 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2017 | 829 | 0.030 |
Why?
|
| Texas | 2 | 2016 | 6311 | 0.030 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 992 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2011 | 2232 | 0.030 |
Why?
|
| Breast | 1 | 2021 | 1344 | 0.030 |
Why?
|
| Skin Neoplasms | 1 | 2010 | 4654 | 0.030 |
Why?
|
| Protein Stability | 1 | 2015 | 370 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2018 | 1489 | 0.030 |
Why?
|
| S100 Proteins | 1 | 2014 | 181 | 0.030 |
Why?
|
| Benzamides | 2 | 2010 | 1832 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2016 | 672 | 0.030 |
Why?
|
| Lymphatic Metastasis | 2 | 2014 | 4844 | 0.030 |
Why?
|
| Proteolysis | 1 | 2015 | 370 | 0.030 |
Why?
|
| Antigens, CD34 | 1 | 2014 | 593 | 0.030 |
Why?
|
| Niacinamide | 1 | 2014 | 421 | 0.030 |
Why?
|
| Mitotic Index | 1 | 2012 | 162 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2016 | 9244 | 0.030 |
Why?
|
| Spinal Neoplasms | 1 | 2017 | 631 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2019 | 12873 | 0.030 |
Why?
|
| Neoplasm Proteins | 1 | 2023 | 3230 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2016 | 2292 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 4938 | 0.020 |
Why?
|
| Retreatment | 1 | 2011 | 452 | 0.020 |
Why?
|
| Cytokines | 1 | 2019 | 2809 | 0.020 |
Why?
|
| Contrast Media | 1 | 2017 | 1472 | 0.020 |
Why?
|
| Mouth Mucosa | 1 | 2010 | 216 | 0.020 |
Why?
|
| Sirolimus | 1 | 2014 | 814 | 0.020 |
Why?
|
| Taxoids | 1 | 2013 | 967 | 0.020 |
Why?
|
| Risk Factors | 2 | 2018 | 17523 | 0.020 |
Why?
|
| Surgeons | 1 | 2016 | 519 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2015 | 3472 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 1303 | 0.020 |
Why?
|
| RNA-Binding Protein EWS | 1 | 2008 | 98 | 0.020 |
Why?
|
| Neoplasm Grading | 1 | 2013 | 1742 | 0.020 |
Why?
|
| Gene Amplification | 1 | 2011 | 731 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 2008 | 169 | 0.020 |
Why?
|
| Prednisolone | 1 | 2008 | 123 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2008 | 290 | 0.020 |
Why?
|
| Deoxycytidine | 1 | 2013 | 1353 | 0.020 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2010 | 726 | 0.020 |
Why?
|
| Extremities | 1 | 2008 | 303 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2016 | 3719 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2014 | 2483 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2018 | 5159 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2008 | 479 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2011 | 1529 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2010 | 2588 | 0.020 |
Why?
|
| Gene Rearrangement | 1 | 2008 | 783 | 0.020 |
Why?
|
| Myocytes, Cardiac | 1 | 2010 | 764 | 0.020 |
Why?
|
| Echocardiography | 1 | 2010 | 1182 | 0.010 |
Why?
|
| Glucocorticoids | 1 | 2008 | 629 | 0.010 |
Why?
|
| Age Factors | 1 | 2013 | 5377 | 0.010 |
Why?
|
| Disease Progression | 1 | 2015 | 6682 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2010 | 4298 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2018 | 14551 | 0.010 |
Why?
|
| United States | 1 | 2020 | 15433 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 2010 | 3842 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 2008 | 1910 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2018 | 8873 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2010 | 5637 | 0.010 |
Why?
|
| Time Factors | 1 | 2015 | 12926 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2008 | 2054 | 0.010 |
Why?
|
| Incidence | 1 | 2010 | 5673 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2012 | 6869 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2008 | 4744 | 0.010 |
Why?
|
| Neoadjuvant Therapy | 1 | 2011 | 4975 | 0.010 |
Why?
|
| Mice | 1 | 2016 | 34495 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2008 | 5178 | 0.010 |
Why?
|
| Animals | 1 | 2016 | 59536 | 0.010 |
Why?
|